Tue, Jul 22, 2014, 10:25 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Synta Pharmaceuticals Corp. (SNTA) Message Board

ajetjock 462 posts  |  Last Activity: Jul 20, 2014 11:24 PM Member since: Mar 11, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • ajetjock ajetjock Jul 20, 2014 11:24 PM Flag

    YES !

    I like the CEO comment !

    If Gollust is the default CEO, we are doing VERY well !

    Mind you that SNTA has EXTREMELY talented Board. Both in the pharma field as well as financial.

    I will post info on all members below and aside from Gollust , pay attention to Friedman. For those who remember Friedman was the INCY (Incyte Corp) CEO. The Co was sold and the stock consequently did VERY well (20 to a high of 70 if I recall.)

    We also know that ALL SNTA insiders OWN a LOT of SNTA stock and NOT ONE has sold ! Not even the former CEO.

    Enjoy:

    Keith R. Gollust Director and Chairman

    Keith R. Gollust has been a member of our Board of Directors since July 2002 and has been our Chairman since September 2002. Mr. Gollust is a private investor and President of Gollust Management, Inc., the general partner of Wyandanch Partners, an investment partnership. In the past, Mr. Gollust has served as a director of numerous public and private companies. Mr. Gollust currently serves as a director of CastleLine Holdings, LLC, an insurance holding company and Script Relief, LLC, a discount prescription drug company. He also is a member of the Board of Trustees of The Julliard School. Mr. Gollust received a B.A. from Princeton University and an MSIA from Carnegie Mellon University. Our Board of Directors has concluded that Mr. Gollust should serve as a director as of the date of this proxy statement based on his past service on the Board of Directors of four other publicly traded companies and his experience as managing general partner of various investment partnerships which gave him responsibility for investing over $1 billion as a fiduciary. [Back to Top]

    Paul A. Friedman, M.D. Director

    Paul A. Friedman, M.D. was the Chief Executive Officer and a Director of Incyte Corporation from November 2001 and and also its President from May 2004 until his retirement in January 2014. Dr. Friedman has been a Director of Durata Therapeutics, Inc. since May 16, 2013. He has been a Non E

    Sentiment: Strong Buy

  • ajetjock ajetjock Jul 16, 2014 11:12 AM Flag

    And every single share I hold is also "still intact".

    Waiting for a much higher price. Like Jennings.

    Sentiment: Strong Buy

  • IPCI DID prove their concept. Once their first drug was approved, it was IMMEDIATELY ready for marketing by PAR Pharma.

    IPCI FLOAT is still MINIMAL !

    Patience and confidence are the KEY to investing. Don't let smoke, mirrors, fear and attempted manipulation by the likes of Maxim to distract you.

    It is only a matter of time before the next drug/s will get FDA approval.

    We are VERY close on at least 3 drugs.

    Again: The float is ONLY: 17 M.

    40% of shares is help by INSIDERS . They want to see it appreciating. Just like the rest of us, LONG investors.

    Focus !

    Sentiment: Strong Buy

  • Reply to

    Technicial BS

    by syenfrout Jul 10, 2014 11:24 AM
    ajetjock ajetjock Jul 11, 2014 12:35 AM Flag

    Well said !

    Especially : "Patience and confidence in the product that you invest in makes the difference. "

    Sentiment: Strong Buy

  • Reply to

    IPCI Fear

    by dr_c6 Jul 9, 2014 11:48 PM
    ajetjock ajetjock Jul 11, 2014 12:30 AM Flag

    Bingo !

    It is funny how every time SHORTS smell blood, even if FOR NO GOOD REASON, as is the case with IPCI, you see NEW IDs around stock boards, ready to enlighten us and tell us how bad IPCI or XXXX is...

    Folks should know that when is FEAR, it is time to BUY. *NEVER* sell in fear or panic .

    FACT is : NOT a thing has changed ! BUT IPCI has FAR MORE CASH on hand than they had before.

    This JOKE for a "downgrade" clearly meant to MANIPULATE the stock price either for shorts or to buy at lower price for longs.

    I am NOT selling as I KNOW that this stock WILL move up fast once the new approvals are announced.

    Just as it did before when the first drug was approved and IMMEDIATELY was ready to be marketed by PAR .

    Sentiment: Strong Buy

  • ajetjock ajetjock Jul 9, 2014 1:12 PM Flag

    And they have said NOTHING meaningful with their report. TOTAL BS !

    Besides how many other more valid firms have we seen coming up with sell/ but AFTER the facts ?

    One thing they did, is create a BUYING opportunity today.

    Sentiment: Strong Buy

  • In fact the company now has FAR MORE cash, the SAME pipleine , same drugs waiting FDA approvals and SAME potential they had few weeks ago.

    The only change is that the report provided shorts an opportunity to sling BS and obviously some of it sticks to the walls.

    Remember: You BUY low (today) you don't sell low. For SURE not in panic and for NO GOOD REASON !

    Sentiment: Strong Buy

  • ajetjock ajetjock Jul 9, 2014 12:48 PM Flag

    NOTHING has changed in regards to future catalysts with the pipeline waiting approval.

    They (IPCI)HAVE proven the concept.

    The only difference is that today, the shorts can sling all kind of MADE UP BS.

    Sentiment: Strong Buy

  • IPCI float is a MINIMAL 17M !

    TOTAL number of shares is also minimal at 23M.

    Go and check these numbers on ANY other pharma...

    Now, ALL pharma survive on issuing stock UNTIL they have enough revenue as a result of FDA approved products.

    This IS simply how the business operates, and it seems that SHORTS trying to pray on naive longs, use this fact against the longs in a campaign of FEAR. Same happens with almost ALL pharma.

    REALITY: As we see from the MINIMAL number of shares, IPCI has been VERY responsible and is NOT issuing too many shares.

    Another reality: INSIDERS own 40% of the shares ! Hence they too have the same interests as long investors : enhance shareholders value.

    I do not know of any other pharma but SNTA, where insiders are so heavily invested in the Co.

    Last...

    With multiple drugs in the pipline, and several pending practically ANY DAY, revenue WILL increase very likely this year.

    Smart investors buy EARLY.

    With the LOW FLOAT we have at IPCI, buying after the news, will cost you. As we have seen with previous approval the stock moved from less than 2 to 6.5 ...FAST.

    IGNORE the SHORTS ! Why would anyone hang around a stock they don't like ??? Unless they want YOU to fear and sell.

    Do YOUR OWN THINKING.

    Sentiment: Strong Buy

  • At May 31, 2014, Intellipharmaceutics' cash totaled $7.3 million, compared with $0.8 million at November 30, 2013.

    Sentiment: Strong Buy

  • Reply to

    What is the next catalyst?

    by hsangha56 Jul 7, 2014 2:36 PM
    ajetjock ajetjock Jul 7, 2014 10:52 PM Flag

    So aside from multiple patents and potential FDA approval, we also have the CEO search ongoing with potential announcement any time. I suspect that announcement to be another significant catalyst.
    Even thought the SNTA board is VERY talented and handles the company just fine.

    Sentiment: Strong Buy

  • Reply to

    Three ANDAs are Overdue

    by dr_c6 Jul 2, 2014 1:24 PM
    ajetjock ajetjock Jul 7, 2014 10:42 AM Flag

    Yep !

    Just sitting and waiting...

    Patience pays.

    Sentiment: Strong Buy

  • Reply to

    This is just the beginning folks.

    by ajetjock Jul 7, 2014 10:01 AM
    ajetjock ajetjock Jul 7, 2014 10:08 AM Flag

    From the Wall St. Cheatsheet article:

    Trading at measly $4.25 per share, Synta may be sitting on a drug that could generate billions in revenue and result in the stock moving magnitudes higher than current levels. Why wouldn’t Pfizer or another competitor step in and scoop it up? The purpose of Synta has a leading anti-cancer drug candidate, ganetespib, which is showing extreme promise. Ganetespib belongs to a new class of drugs known as heat shock protein 90 (Hsp 90) inhibitors. Hsp90 plays a role in the maturation of client proteins, which help cells growth, divide, and survive. Compared to healthy cells, cancer cells are more dependent on elevated levels of Hsp90 to proliferate. As such, inhibiting the production of Hsp90 could stop certain types of cancer. Unlike other targeted therapies that seek out specific mutations — like Pfizer’s Xalkori, which are specifically tailored to seek out and attack specific mutated cells — Hsp90 inhibitors are believed to be able to disrupt several signaling pathways simultaneously to stop tumor cell proliferation.

    Why am I so excited about this company? Well, the data is pretty convincing. Treatment with ganetespib has been shown in preclinical models to reduce some aggressive features of tumors, such as the ability to induce the growth of new blood vessels, the ability to spread to other organs in the body, and to resist attack by traditional therapies, such as chemo. Synta is primarily focusing on developing ganetespib as a treatment for non-small-cell lung cancer (or, NSCLC) breast cancer and colorectal cancer. If approved, the drug is expected to hit annual peak sales of $425 million to $600 million.

    Here is the one problem: While its anticancer properties are not in question, successful formulation of a drug that can actively treat cancer in patients is indeed in question. It has been tough to move from the biochemistry to the in vivo therapy. If you are looking for the one company with a real shot to get FDA approval

    Sentiment: Strong Buy

  • We have a long move UP ahead.

    Sentiment: Strong Buy

  • Reply to

    News

    by ziddox Jul 3, 2014 12:16 PM
    ajetjock ajetjock Jul 3, 2014 2:21 PM Flag

    As far as patents go. We all know this is NOT the first or only patent SNTA has.

    Does any of you keep a running total of their patents ? How many patents do they hold ?

    Sentiment: Strong Buy

  • ajetjock ajetjock Jul 2, 2014 1:18 PM Flag

    I agree.

    SNTA board is VERY talented and has the experience to prove it.

    They clearly know what they are doing.

    Just ask INCY shareholders for example.

    Sentiment: Strong Buy

  • They don't MANUFACTURE news to pump the price. Even though INSIDERS own 40% of IPCI.

    Once a company appears to be more in the stock PR business, REAL news gets lost and REAL investors lose interest.

    IPCI management acts *RESPONSIBLY* !

    The same applies to their line of credit via shelf registration. Contrary to Gregory's BS, they don't just print paper, its a CREDIT line to be available WHEN NEEDED ! (Excellent indicator.)

    Fact is: FLOAT is still MINIMAL and news will be MEANINGFUL, when arrive.

    Sentiment: Strong Buy

  • ajetjock ajetjock Jul 2, 2014 9:12 AM Flag

    Sadly....This "gross incompetence" version is about the only explanation that makes sense.

    I am wiling to guess it MAY have had to do with recent investment conf. they just had ?!

    Sentiment: Strong Buy

  • ajetjock by ajetjock Jun 30, 2014 10:59 AM Flag

    From Wiki:

    Fr history: 2008 Financial Crisis
    During the 2008 financial crisis Caxton Associates did not erect gates freezing investor capital in their Caxton Global Investments fund.[11] As reported the fund saw client redemptions totalling 27% of assets under management through 2008–2009—while returning 13% for the year.[11] The redemptions were reportedly born out of cash strapped clients many of whose asset allocations were gated and frozen at other investment management companies Caxton Associates is a global macro hedge fund founded by Bruce Kovner in 1983 and is headquartered in New York City.[1][3] The firm also has offices in London, Sydney, and Princeton, New Jersey. As a global macro hedge fund, Caxton Associates identifies investments according to their research of global markets and analysis of worldwide economic trends ...In 2008, Bruce Kovner stepped back from trading and appointed Andrew Law as Caxton’s Chief Investment Officer. In 2011, Law was appointed as the Chairman, CEO and controlling general partner of Caxton Associates, following the retirement of Kovner.[5] Law joined the London office in 2003 from Goldman Sachs, where he was Managing Director and head of FICC proprietary trading in London.[6]

    2008 Financial Crisis
    During the 2008 financial crisis Caxton Associates did not erect gates freezing investor capital in their Caxton Global Investments fund.[11] As reported the fund saw client redemptions totalling 27% of assets under management through 2008–2009—while returning 13% for the year.[11] The redemptions were reportedly born out of cash strapped clients many of whose asset allocations were gated and frozen at other investment management companies... In 2010 it was reported that since 1983 Caxton Associates had returned $12.8 billion to clients whilst managing $6 billion; ranking second amongst managers who have returned more than they currently manage.

    Sentiment: Strong Buy

  • Reply to

    Something is comming for sure.

    by maxwellsmart322 Jun 28, 2014 2:17 PM
    ajetjock ajetjock Jun 30, 2014 10:44 AM Flag

    I would also HIGHLY suggest investors Google / Wiki: Caxton !
    Caxton is HIGHLY invested in SNTA.

    READ about them !!!

    Sentiment: Strong Buy

SNTA
4.15+0.08(+1.97%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.